Agilent Technologies (A) Advances +9.6% on Strong Q3 Results and Raised 2026 Guidance
Key Takeaways
- Agilent Technologies shares rose roughly 9.6% over the trailing 30 days, trading near $173.
- Fiscal third-quarter results beat expectations, with revenue up 7.3% on a core basis and adjusted EPS up 14% year over year, excluding tariff refunds.
- Management raised full-year fiscal 2026 guidance, citing improving end markets, renewed China momentum, and strong pharma and instrument demand.
- Growth is being driven by liquid chromatography (LC) and gas chromatography (GC) replacement cycles, GLP-1-related pharma demand, and the Ignite operating system.
- The Advanced Therapeutics CDMO business grew nearly 30% in the quarter, while instrument book-to-bill remained above 1.0 for a 10th consecutive quarter.
Market Snapshot and Recent Performance
Agilent Technologies shares have extended a multi-month advance, gaining about 9.6% over the trailing 30 days to trade near $173. The move followed a stronger-than-expected fiscal third-quarter report and an upward revision to full-year guidance. Momentum reflects improving demand across pharmaceutical, chemicals and advanced materials, and diagnostics end markets, supported by an ongoing instrument replacement cycle and steady market-share gains. Broader life-sciences and lab-tools sentiment has also firmed as customer capital budgets stabilize and demand in China recovers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Agilent Technologies (A) Business Overview and Competitive Position
Agilent Technologies (A) is a global provider of analytical and clinical laboratory technologies, delivering instruments, software, consumables, and services across the life sciences, diagnostics, and applied chemical markets. Its portfolio includes liquid chromatography (LC), gas chromatography (GC), and mass spectrometry systems, complemented by a substantial recurring-revenue base of consumables, services, and software through its CrossLab group. The company reports results across three segments: the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. Agilent generated approximately $6.95 billion in revenue in fiscal 2025 and employs roughly 18,000 people worldwide. Key competitive strengths include a large installed base, a high-margin recurring revenue stream, and a diversified geographic footprint that has helped the company win share across workflows and regions.
Recent Developments Driving A
Agilent's third-quarter fiscal 2026 results, reported in late August, were the primary catalyst behind the recent share advance. Revenue reached $1.88 billion, up 8.1% on a reported basis and 7.3% on a core basis, while adjusted earnings per share came in at $1.62, or $1.56 excluding a tariff-refund benefit, up 14% year over year. Both figures exceeded consensus estimates.
Pharma revenue grew 12% in the quarter, with GLP-1-related demand rising more than 70% year over year. The Advanced Therapeutics contract development and manufacturing (CDMO) business grew nearly 30%, and China revenue increased 9%, well ahead of expectations. Instrument demand remained healthy, with book-to-bill above 1.0 for a 10th straight quarter and strong early traction for new products such as the 9500 Triple Quad ICP-MS and flagship GC systems.
Management raised its full-year fiscal 2026 outlook to revenue of $7.49 billion to $7.51 billion and adjusted EPS of $6.18 to $6.21, or $6.12 to $6.15 excluding tariff refunds. The company also highlighted margin expansion from its Ignite transformation program, with operating margin up 210 basis points year over year excluding refunds. Other recent developments include the closing of the Biocare acquisition in late June, new CE-IVD-labeled TapeStationDx products for clinical next-generation sequencing quality control, and refreshed board leadership. From what I see, the consistency in instrument demand stands out as particularly supportive.
2026 Outlook and What Investors Should Watch
Looking ahead, the key drivers for Agilent include the pace of the LC and GC replacement cycles, sustained pharma and GLP-1-related demand, and the trajectory of the China recovery. Investors will also monitor the ramp of the Advanced Therapeutics CDMO capacity expansions, where new production trains are expected to begin contributing over the next several quarters, as well as continued execution of the Ignite efficiency program. Macroeconomic factors such as tariffs, currency movements, and geopolitical uncertainty remain relevant, as do semiconductor and advanced-materials spending trends. The company's fourth-quarter guidance implies continued mid-single-digit core growth, and upcoming earnings releases will provide further clarity on whether current momentum carries into fiscal 2027. I’m watching this closely as execution on capacity and China trends could shape the next leg higher.
Incorporating Systematic AI Signals
In my research process, I often review Tickeron’s Trending AI Robots page to complement fundamental analysis with systematic trading signals. The page highlights top-performing AI-driven bots across strategies and timeframes, allowing users to compare automated approaches that align with specific objectives and risk levels without requiring an exhaustive scan of every available tool.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
A saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for A moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 71 similar instances where the indicator exited the overbought zone. In 48 of the 71 cases the stock moved lower. This puts the odds of a downward move at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 18 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on A as a result. In 54 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for A just turned positive on September 18, 2026. Looking at past instances where A's MACD turned positive, the stock continued to rise in 27 of 45 cases over the following month. The odds of a continued upward trend are 60%.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 189 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 132 of 202 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.707) is normal, around the industry mean (72.578). P/E Ratio (34.558) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). A has a moderately high Dividend Yield (0.006) as compared to the industry average of (0.001). P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of measurement and monitoring instruments
Industry MedicalSpecialties
Advertisement